News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Advanced Search
  • Nov 20, 2019

    SAN DIEGO, November 20, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...

  • Nov 19, 2019

    SAN DIEGO, November 19, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...

  • Nov 13, 2019

    SAN DIEGO, November 13, 2019 — Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial...

  • Nov 7, 2019
    Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® | Announced partnership with Arcellx to develop SparX proteins used in cell therapies | Jazz advances PF743 (JZP-458) to pivotal Phase 2/3 Study expected to be initiated later this year; Jazz also announced FDA fast track designation for JZP-458, for the treatment of ALL/LBL | Earned $13.5 million in development and regulatory milestone payments

    SAN DIEGO, November 7, 2019 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...

  • Nov 6, 2019

    Conference: Jefferies 2019 London Healthcare Conference Date: Wednesday, November 20, 2019 Time: 4:00 p.m. GMT (8:00 a.m. PST) Webcast: Interested parties can access the live audio webcast and...

  • Oct 24, 2019

    SAN DIEGO, October 24, 2019-- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve...

  • Oct 14, 2019
    Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks | Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-approved PF708 product for therapeutic equivalence

    SAN DIEGO, October 14, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study...

  • Oct 11, 2019
    New Exclusive Commercialization Agreements in South Korea, Canada, and Israel | Submission of Marketing Authorization Application for PF708 in Saudi Arabia | Potential approval of PF708 in the EU as early as the second half of 2020

    SAN DIEGO, October [11], 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea...

  • Oct 7, 2019
    Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval. Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019

    SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for PF708...

  • Sep 16, 2019

    SAN DIEGO, September 16, 2019—Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...

Show 5102550100 per page